Selected videos of the 54th ASCO Congress
1-5 June 2018, Chicago, USA
The Editors of the 54th ASCO Congress Medicom Conference Report, Dr Erlinda Gordon and Dr Sant Chawla, congratulate ASCO with this year’s theme “Delivering Discoveries: Expanding the Reach of Precision Medicine” for another successful and well-attended meeting.
The highlights of the ASCO2018 annual meeting are presented in the ASCO2018 Medicom Conference Report, and include advances in screening and biomarker development for numerous types of cancer. A major theme in the report is the mixed results on whether to use monotherapy or combination therapy. Another highlight is the successful use of CAR T-cell therapy in blood cancers.
The ASCO2018 Medicom Conference Report also includes two Editor selected ASCO2018 Congress videos per chapter.
Capivasertib plus paclitaxel increases PFS compared with paclitaxel alone
Denosumab improves DFS in postmenopausal women with Breast Cancer
Pembrolizumab improves survival, reduces toxicity over chemotherapy in low PD-L1–expressing NSCLC
Frontline pembrolizumab and chemotherapy a new standard of care in metastatic squamous NSCLC
BCMA-directed CAR T cells yield deep, durable continued from page 1A responses in relapsed/refractory Multiple Myeloma
Once-weekly dosing with carfilzomib promising for relapsed/refractory Multiple Myeloma
Adjuvant Nivolumab Continues to Outperform High-Dose Ipilimumab in Resected Stage III/IV Melanoma
4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.
Regorafenib shows promise in osteosarcoma, no benefit in Liposarcoma
Maintenance therapy improves outcomes in Rhabdomyosarcoma
| Studies help inform optimal use of CD19-Targeted CAR T-cell therapy in |
Non-chemo/immunotherapy combination efficacious for advanced follicular lymphoma in RELEVANCE Trial
Immunotherapy now standard for some patients with CRC
Development of a cell-free DNA multicancer screening test
| LOXO-292 phase I results show promise in the treatment of RET-altered Cancers |